Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL


Brad S. Kahl, MD, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma.

Brad S. Kahl, MD, a medical oncologist at Siteman Cancer Center and a professor of medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).

The management of patients with ​relapsed/refractory iNHL can be challeng​ing as many factors influence the decision-making process, says Kahl. 

Patient-specific factors such as age, comorbidities, and goals of treatment should be considered, Kahl explains. Additionally, it is important to note all prior treatments the patient had received and how well they responded to them. 

Notably, if a patient ​derived a substantial response from a frontline therapy with minimal toxicity, it may be reasonable to offer that therapy again. However, ​as there are many ​therapeutic options in this space, this does not happen often, Kahl concludes.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD